 Entera Bio Ltd NASDAQ: ENTX has presented the 6-month bone mineral density BMD data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone PTH, for osteoporosis. The Phase 2 Dose-Ranging study showed clinically significant changes in increases in BMD at the spine, femoral neck, and total hip. 